- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| Di | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| Di | EXTRAWELL PHAR (00858): CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 31.12.25 | EXTRAWELL PHAR (00858): CHANGE OF BUILDING NAME OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY ... | 3 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): CHANGE OF CHIEF EXECUTIVE OFFICER | 3 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): INTERIM REPORT 2025/26 | 1 | HKEx | ||
| 19.12.25 | EXTRAWELL PHAR (00858): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 02.12.25 | EXTRAWELL PHAR (00858): MAJOR TRANSACTION - PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS | - | HKEx | ||
| 28.11.25 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025 | 1 | HKEx | ||
| 20.11.25 | EXTRAWELL PHAR (00858): PROFIT WARNING | 2 | HKEx | ||
| 13.11.25 | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx | ||
| 10.09.25 | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.09.25 | EXTRAWELL PHAR (00858): COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE AND BUSINESS UPDATE | - | HKEx | ||
| 22.08.25 | EXTRAWELL PHAR (00858): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 AUGUST 2025 | 2 | HKEx | ||
| 15.08.25 | EXTRAWELL PHAR (00858): ISSUE OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 28.07.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx | ||
| 28.07.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 66,30 | -2,50 % | EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka | TOKYO (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary... ► Artikel lesen | |
| CSPC PHARMA | 1,075 | -1,96 % | CSPC PHARMA (01093): INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025 | ||
| SELLAS LIFE SCIENCES | 3,975 | +1,79 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 22,970 | +2,50 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,580 | -0,29 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 426,90 | +0,42 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) | ||
| ENZON PHARMACEUTICALS | 0,030 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Announce Amendment to Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,938 | -4,30 % | Opus Genetics: BTIG startet Bewertung mit Kaufempfehlung wegen Fokus auf Netzhauterkrankungen | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 5,300 | 0,00 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,560 | +3,23 % | GALECTIN THERAPEUTICS INC - 8-K, Current Report | ||
| BIODEXA PHARMACEUTICALS | 2,100 | 0,00 % | Biodexa Pharmaceuticals PLC: Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary | January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq:... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 12,200 | 0,00 % | NovaBay plunges on sales agreement for $100M stock | ||
| NEURIZON THERAPEUTICS | 0,042 | -2,33 % | NEURIZON THERAPEUTICS LIMITED: Notice of General Meeting/Proxy Form | ||
| CIPHER PHARMACEUTICALS | 9,100 | -1,09 % | Cipher Pharmaceuticals GAAP EPS of $0.21 beats by $0.08, revenue of $12.83M misses by $0.53M |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.